Case File
efta-efta00769128DOJ Data Set 9OtherFrom: "Zelin, Barry"
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00769128
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: "Zelin, Barry"
To: "Jeffrey Epstein" <[email protected]>
Subject: RE:
Date: Tue, 24 Nov 2009 16:03:23 +0000
What is it with these people? I am trying to understand why they all lost their way. Some where, between leaving home
and going off to college and entering the work force, "ethics "were abandoned for gold. The biggest screwing I ever got was
from a religious Jew Joseph Gutnick of Australia, a true billionaire,. He really hurt me. My life would have been a lot easier
had he lived up to his obligation to me. I was going to take him to the Beth Din, the Jewish Court. On another more
important issue to me,
have you any contacts on the
street that might make sense W. Imo
h
interview with? Everyone I know is dead.
Barry W. Zelin
Axiom Capital Management
780 Third Avenue, 43rd Floor
NY, NY 10017
OFFICE
CELL:
FAX:
From: Jeffrey Epstein [mallto:[email protected]]
Sent: Tuesday, November 24, 2009 10:24 AM
To: Zetin, Barry
Subject: Re:
it worked,,, check out rothstein epstein florida fraud
On Tue, Nov 24, 2009 at 10:21 AM, Zelin, Barry <
Hey Boy,
I said a prayer for your well being at the wall, did you feel it?
Barry W. Zelin
Axiom Capital Management
780 Third Avenue, 43rd Floor
NY, NY 10017
OFFICE
CELL:
FAX:
> wrote:
This email message is for the individual use of the intended recipient's and may contain confidential and privileged information. Any unauthorized review,
use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the
original message. Any views expressed in this message are those of the individual sender, except where the sender specifically states them to be the
views of Axiom Capital Management.
Axiom Capital Management Inc. reviews and archives outgoing and incoming email. Such may be produced at the request of regulators and/or in
connection with judicial/arbitral proceedings. Sender accepts no liability for any errors or omissions arising as a result of transmission. Use by other than
intended recipients is prohibited. This transmission is neither an offer nor a solicitation of an offer to purchase or liquidate securities. Opinions or
EFTA00769128
estimates constitute Axiom Capital Management Inc.'s views, beliefs and judgment at this moment and are subject to change without notice. Information
upon which the material contained in this transmission is based was obtained from sources believed to be reliable but has not been verified. Additional
information is available upon request.
Axiom Capital Management Inc., its affiliates and respective directors, officers and employees may purchase or liquidate securities mentioned herein as
agent or principal.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments.
This email message is for the individual use of the intended recipient's and may contain confidential and privileged information. Any unauthorized review,
use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the
original message. Any views expressed in this message are those of the individual sender, except where the sender specifically states them to be the
views of Axiom Capital Management.
Axiom Capital Management Inc. reviews and archives outgoing and incoming email. Such may be produced at the request of regulators and/or in
connection with judicial/arbitral proceedings. Sender accepts no liability for any errors or omissions arising as a result of transmission. Use by other than
intended recipients is prohibited. This transmission is neither an offer nor a solicitation of an offer to purchase or liquidate securities. Opinions or
estimates constitute Axiom Capital Management Inc.'s views, beliefs and judgment at this moment and are subject to change without notice. Information
upon which the material contained in this transmission is based was obtained from sources believed to be reliable but has not been verified. Additional
information is available upon request.
Axiom Capital Management Inc., its affiliates and respective directors, officers and employees may purchase or liquidate securities mentioned herein as
agent or principal.
EFTA00769129
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.